Jade Biosciences
NASDAQ · JBIO·Cambridge, MA·Small-cap·Phase 1
Clinical-stage biotech developing best-in-class monoclonal antibodies for autoimmune diseases. Lead asset JADE101 (anti-APRIL) targets IgA nephropathy, with JADE201 advancing toward Phase 1 in rheumatoid arthritis. Formed via 2025 merger with Aerovate Therapeutics.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Jade Biosciences Company Presentation — March 2026 | Corporate overview | April 6, 2026 | 35 |